Solvay

Impairment-driven effects

25/06/20 -"We have factored in the potential c.€1.5bn impairment on the composites and (shale) oil & gas business, due to the subdued future business expectations. "

PDF page sample
Pages
58
Language
English
Published on
25/06/20
Download
You may also be interested by these reports :
23/01/26
BASF’s preliminary estimates for FY 2025 remained broadly in line with street expectations on core operations but outperformed on the back of ...
22/01/26
We have revised down our FY 2026 EPS forecast to CHF 0.75 (vs. CHF 0.90 previously), reflecting a more cautious outlook for the year. Our sales ...
21/01/26
We have lowered our EPS estimates for FY25/FY26 to -€0.91/€0.45, from €1.15/€3.57, reflecting weaker sales expectations (FY25/FY26: €5.5bn/€5.6bn vs ...
14/01/26
Cost discipline helps, but delivery still falls short

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO